Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROfound-CN: olaparib versus enzalutamide or abiraterone in BRCA1/2-mutated mCRPC after prior novel hormonal agent failure
CTR20221020Phase 4Active
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of olaparib in prostate cancer (PCa), sponsored by AstraZeneca. Started Dec 2022; status: active.
02
Drugs
olaparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20221020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221020.